Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy
| dc.contributor.author | Caravaca-Fontán, F. | * |
| dc.contributor.author | Cavero, T. | * |
| dc.contributor.author | Díaz-Encarnación, M. | * |
| dc.contributor.author | Cabello, V. | * |
| dc.contributor.author | Ariceta, G. | * |
| dc.contributor.author | Quintana, L.F. | * |
| dc.contributor.author | Marco, H. | * |
| dc.contributor.author | Barros, X. | * |
| dc.contributor.author | Ramos, N. | * |
| dc.contributor.author | Rodríguez-Mendiola, N. | * |
| dc.contributor.author | Cruz, S. | * |
| dc.contributor.author | Fernández-Juárez, G. | * |
| dc.contributor.author | Rodríguez, A. | * |
| dc.contributor.author | Pérez De José, A. | * |
| dc.contributor.author | Rabasco, C. | * |
| dc.contributor.author | Rodado, R. | * |
| dc.contributor.author | Fernández, L. | * |
| dc.contributor.author | Pérez-Gómez, V. | * |
| dc.contributor.author | Ávila, A. | * |
| dc.contributor.author | Bravo Gonzalez-Blas, Luis Maria | * |
| dc.contributor.author | Espinosa, N. | * |
| dc.contributor.author | Allende, N. | * |
| dc.contributor.author | Sanchez De La Nieta, M.D. | * |
| dc.contributor.author | Rodríguez, E. | * |
| dc.contributor.author | Rivas, B. | * |
| dc.contributor.author | Melgosa, M. | * |
| dc.contributor.author | Huerta, A. | * |
| dc.contributor.author | Miquel, R. | * |
| dc.contributor.author | Mon, C. | * |
| dc.contributor.author | Fraga, G. | * |
| dc.contributor.author | De Lorenzo, A. | * |
| dc.contributor.author | Draibe, J. | * |
| dc.contributor.author | González, F. | * |
| dc.contributor.author | Shabaka, A. | * |
| dc.contributor.author | López-Rubio, M.E. | * |
| dc.contributor.author | Fenollosa, M.Á. | * |
| dc.contributor.author | Martín-Penagos, L. | * |
| dc.contributor.author | Da Silva, I. | * |
| dc.contributor.author | Titos, J.A. | * |
| dc.contributor.author | Rodríguez De Córdoba, S. | * |
| dc.contributor.author | Goicoechea De Jorge, E. | * |
| dc.contributor.author | Praga, M. | * |
| dc.date.accessioned | 2025-09-08T12:22:16Z | |
| dc.date.available | 2025-09-08T12:22:16Z | |
| dc.date.issued | 2023 | |
| dc.identifier.citation | Caravaca-Fontán F, Cavero T, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, et al. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy. Kidney360. 2023;4(5):659-72. | |
| dc.identifier.issn | 2641-7650 | |
| dc.identifier.other | https://portalcientifico.sergas.gal//documentos/648fd829f1a6cb24f859d4e9 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11940/21285 | |
| dc.description.abstract | BackgroundC3 glomerulopathy is a rare kidney disease, which makes it difficult to collect large cohorts of patients to better understand its variability. The aims of this study were to describe the clinical profiles and patterns of progression of kidney disease.MethodsThis was a retrospective, observational cohort study. Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. Study population was divided into clinical profiles by combining the following predictors: eGFR under/above 30 ml/min per 1.73 m2, proteinuria under/above 3.5 g/d, and histologic chronicity score under/above 4. The change in eGFR and proteinuria over time was evaluated in a subgroup with consecutive measurements of eGFR and proteinuria.ResultsOne hundred and fifteen patients with a median age of 30 years (interquartile range 19-50) were included. Patients were divided into eight clinical profiles. Kidney survival was significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d, both in those presenting with an eGFR under/above 30 ml/min per 1.73 m2. The median eGFR slope of patients who reached kidney failure was -6.5 ml/min per 1.73 m2per year (interquartile range -1.6 to -17). Patients who showed a reduction in proteinuria over time did not reach kidney failure. On the basis of the rate of eGFR decline, patients were classified as faster eGFR decline (?5 ml/min per 1.73 m2per year), slower (<5 ml/min per 1.73 m2per year), and those without decline. A faster eGFR decline was associated with higher probability of kidney failure.ConclusionsKidney survival is significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d regardless of baseline eGFR, and a faster rate of decline in eGFR is associated with higher probability of kidney failure. | |
| dc.description.sponsorship | Analyses in this publication were conducted through a research collaboration with Novartis Pharma AG, who provided funding and also provided input to the analysis protocol. Work in this study was supported by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grant PI16/01685 and PI19/1624, and Red de Investigacion Renal (RedInRen) (RD12/0021/0029) (to MP), the Autonomous Region of Madrid (S2017/BMD-3673) (to MP). SRdeC is supported by Ministerio de Economia y Competitividad grant PID2019-104912RB-I00 y Autonomous Region of Madrid grant S2017/BMD-3673. | |
| dc.language | eng | |
| dc.rights | Attribution 4.0 International (CC BY 4.0) | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.mesh | Humans | * |
| dc.subject.mesh | Kidney | * |
| dc.subject.mesh | Kidney Diseases | * |
| dc.subject.mesh | Disease Progression | * |
| dc.title | Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy | |
| dc.type | Artigo | |
| dc.authorsophos | Caravaca-Fontán, F.; Cavero, T.; Díaz-Encarnación, M.; Cabello, V.; Ariceta, G.; Quintana, L.F.; Marco, H.; Barros, X.; Ramos, N.; Rodríguez-Mendiola, N.; Cruz, S.; Fernández-Juárez, G.; Rodríguez, A.; Pérez De José, A.; Rabasco, C.; Rodado, R.; Fernández, L.; Pérez-Gómez, V.; Ávila, A.; Bravo, L.; Espinosa, N.; Allende, N.; Sanchez De La Nieta, M.D.; Rodríguez, E.; Rivas, B.; Melgosa, M.; Huerta, A.; Miquel, R.; Mon, C.; Fraga, G.; De Lorenzo, A.; Draibe, J.; González, F.; Shabaka, A.; López-Rubio, M.E.; Fenollosa, M.Á.; Martín-Penagos, L.; Da Silva, I.; Titos, J.A.; Rodríguez De Córdoba, S.; Goicoechea De Jorge, E.; Praga, M. | |
| dc.identifier.doi | 10.34067/kid.0000000000000115 | |
| dc.identifier.sophos | 648fd829f1a6cb24f859d4e9 | |
| dc.issue.number | 5 | |
| dc.journal.title | Kidney360 | * |
| dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Nefroloxía | |
| dc.page.initial | 659 | |
| dc.page.final | 672 | |
| dc.relation.projectID | Novartis Pharma AG | |
| dc.relation.projectID | Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) [PI16/01685, PI19/1624] | |
| dc.relation.projectID | Red de Investigacion Renal (RedInRen) [RD12/0021/0029] | |
| dc.relation.projectID | Autonomous Region of Madrid [S2017/BMD-3673] | |
| dc.relation.projectID | Ministerio de Economia y Competitividad [S2017/BMD-3673, PID2019-104912RB-I00] | |
| dc.relation.publisherversion | https://doi.org/10.34067/kid.0000000000000115 | |
| dc.rights.accessRights | openAccess | * |
| dc.subject.keyword | AS A Coruña | |
| dc.subject.keyword | CHUAC | |
| dc.typefides | Artículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis) | |
| dc.typesophos | Artículo Original | |
| dc.volume.number | 4 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)







